| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/11/2008 | EP1928890A2 Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
| 06/11/2008 | EP1928889A1 Pharmaceutically acceptable salts and hydrates of risedronic acid |
| 06/11/2008 | EP1928886A1 Pyridine derivatives and their use in the treatment of psychotic disorders |
| 06/11/2008 | EP1928882A2 (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use |
| 06/11/2008 | EP1928881A2 Prodrugs of active agents |
| 06/11/2008 | EP1928880A1 Crystalline forms of [(1r), 2s]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester |
| 06/11/2008 | EP1928879A2 Fused heterocyclic compounds useful as kinase modulators |
| 06/11/2008 | EP1928878A1 Methods for the preparation of hcv polymerase inhibitors |
| 06/11/2008 | EP1928877A1 Purine derivatives for the treatment of viral or allergic diseases and cancers |
| 06/11/2008 | EP1928876A1 Purine derivatives having immuno-modulating properties |
| 06/11/2008 | EP1928875A1 2-amino-7,8-dihydro-6h-pyridoý4,3-d¨pyrimidin-5-ones |
| 06/11/2008 | EP1928874A1 Heterobicyclic compounds as glucokinase activators |
| 06/11/2008 | EP1928872A1 Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles |
| 06/11/2008 | EP1928871A2 Bicyclic derivatives as modulators of voltage gated ion channels |
| 06/11/2008 | EP1928868A1 Iminooxazolidine derivatives and use thereof |
| 06/11/2008 | EP1928867A1 2-aminoethoxyacetic acid derivatives and their use in treating thromboembolic disorders |
| 06/11/2008 | EP1928866A1 Substituted indazoles as inhibitors of phosphodiesterase type-iv |
| 06/11/2008 | EP1928865A1 Novel high affinity thiophene-based and furan-based kinase ligands |
| 06/11/2008 | EP1928864A1 Novel cycloalkane carboxamides as factor xa inhibitors |
| 06/11/2008 | EP1928863A2 Pharmaceutical dosage forms and compositions comprising lecoztan |
| 06/11/2008 | EP1928862A1 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity |
| 06/11/2008 | EP1928861A1 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
| 06/11/2008 | EP1928860A1 Novel 2,3-dihydroindole compounds |
| 06/11/2008 | EP1928859A1 Pyrazole derivates as cannabinoid receptor modulators |
| 06/11/2008 | EP1928858A1 Solid salt forms of a pyrrole substituted 2-indolinone |
| 06/11/2008 | EP1928856A1 Quinoline compounds capable of binding the cb2 and/or the 5-ht6 receptor |
| 06/11/2008 | EP1928851A1 Vitamin d derivatives active on the vitamin d nuclear receptor, preparation and uses thereof |
| 06/11/2008 | EP1928850A2 Agents for preventing and treating disorders involving modulation of the ryr receptors |
| 06/11/2008 | EP1928849A1 New crystallization process of quetiapine hemifumarate |
| 06/11/2008 | EP1928848A2 Sphingosine kinase inhibitors and methods of their use |
| 06/11/2008 | EP1928847A2 Theramutein modulators |
| 06/11/2008 | EP1928846A2 Triazole compounds that modulate hsp90 activity |
| 06/11/2008 | EP1928845A2 Aminodiazepines as toll-like receptor modulators |
| 06/11/2008 | EP1928843A1 Bis-aryl urea compounds for the treatment of protein kinase-mediated diseaes |
| 06/11/2008 | EP1928842A1 4-phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| 06/11/2008 | EP1928840A1 1h-pyrazole 4-carboxylamides, their preparation and their use as 11beta-hydroxysteroid dehydrogenase |
| 06/11/2008 | EP1928837A2 18,21-didesoxymacbecin derivatives for the treatment of cancer |
| 06/11/2008 | EP1928836A1 Substituted 4-phenyltetrahydroisoquinolines, method of producing them, their use as medicament, and also medicament containing them |
| 06/11/2008 | EP1928835A1 Alkyl sulfoxide quinolines as nk-3 receptor ligands |
| 06/11/2008 | EP1928834A1 Alkylnitrile quinolines, as nk-3 receptor ligands |
| 06/11/2008 | EP1928833A1 Novel quinoline compounds capable of binding at the cb2 receptor |
| 06/11/2008 | EP1928829A1 Piperidine derivatives as antagonists of the cc chemokine receptor ccr1 and their use as anti-inflammatory agents |
| 06/11/2008 | EP1928826A1 Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors |
| 06/11/2008 | EP1928824A1 Process for annealing amorphous atorvastatin |
| 06/11/2008 | EP1928821A1 Carboxamide derivatives as muscarinic receptor antagonists |
| 06/11/2008 | EP1928807A2 Oncogenic regulatory rnas for diagnostics and therapeutics |
| 06/11/2008 | EP1928594A2 Method for production of single- and multi-layer microcapsules |
| 06/11/2008 | EP1928553A2 N-(1-pyrene)maleimide, iaans and 5-(bromomethyl) fluorescein for covalent binding to md-2 and effect on the immune response |
| 06/11/2008 | EP1928505A2 Aptamers that bind thrombin with high affinity |
| 06/11/2008 | EP1928501A2 Kit for parenteral administration of medicaments |
| 06/11/2008 | EP1928500A2 Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
| 06/11/2008 | EP1928492A2 Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
| 06/11/2008 | EP1928480A2 Methods for managing adipocyte fat accumulation |
| 06/11/2008 | EP1928476A1 Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal |
| 06/11/2008 | EP1928475A2 Antiviral phosphoramidates of 4'-substituted pronucleotides |
| 06/11/2008 | EP1928474A1 Use of glucosylated hydroxystilbenes for the prevention and treatment of eye pathologies |
| 06/11/2008 | EP1928473A1 Combination of polychitosamine and fibrate for the prevention and treatment of hyperlipidemia |
| 06/11/2008 | EP1928472A2 Composition and method for use in cartilage affecting conditions |
| 06/11/2008 | EP1928471A2 Prevention and treatment of gastrointestinal and bladder disorders associated with chemotherapy or radiation therapy using active vitamin d compounds |
| 06/11/2008 | EP1928470A2 Modulators of hypoxia inducible factor-1 and related uses for the treatment of ocular disorders |
| 06/11/2008 | EP1928469A1 Fulvestrant formulation |
| 06/11/2008 | EP1928468A2 Estriol therapy for autoimmune and neurodegenerative diseases and disorders |
| 06/11/2008 | EP1928467A2 N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof |
| 06/11/2008 | EP1928466A2 Pdt treatment method for cellulites and cosmetic use |
| 06/11/2008 | EP1928465A1 Benzodiazepine derivatives for treating hepatitis c infection |
| 06/11/2008 | EP1928464A2 Novel parenteral carbamazepine formulation |
| 06/11/2008 | EP1928463A2 Method of using potassium channel inhibiting compounds |
| 06/11/2008 | EP1928462A1 Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
| 06/11/2008 | EP1928461A1 Pyrimidine compounds as serotonin receptor modulators |
| 06/11/2008 | EP1928460A2 Mc4r-agonists for the treatment of urinary tract dysfunction |
| 06/11/2008 | EP1928459A2 Tablet-type controlled-release preparation containing cinnarizine and dimenhydrinate for combating vertigo |
| 06/11/2008 | EP1928458A2 Use of inhibitors of the na+/h+ exchanger, subtype 5 (nhe5), to improve memory retention |
| 06/11/2008 | EP1928457A2 Quinolines and their therapeutic use |
| 06/11/2008 | EP1928456A2 Substituted pyrazole compounds |
| 06/11/2008 | EP1928455A1 Anilinopyrazole derivatives useful for the treatment of diabetes |
| 06/11/2008 | EP1928454A2 Pyridone derivatives for modulating stress-activated protein kinase system |
| 06/11/2008 | EP1928453A2 Methods and compositions for the preventioin and treatment of kidney disease |
| 06/11/2008 | EP1928452A2 Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment |
| 06/11/2008 | EP1928451A1 Methods for treating substance-related disorders |
| 06/11/2008 | EP1928450A2 Treating premature ejaculation using gabapentin and pregabalin prodrugs |
| 06/11/2008 | EP1928449A1 Acetylcysteine composition and uses therefor |
| 06/11/2008 | EP1928448A1 ASSOCIATION OF ß3 RECEPTOR AGONIST AND MONOAMINE REUPTAKE INHIBITORS, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND THERAPEUTIC USE THEREOF |
| 06/11/2008 | EP1928447A2 Vanilla planifolia extract, method for obtaining same, and cosmetic or dermatological composition containing same |
| 06/11/2008 | EP1928446A2 Milnacipran for the long-term treatment of fibromyalgia syndrome |
| 06/11/2008 | EP1928445A1 Method and means of preventing and treating sleep disordered breathing |
| 06/11/2008 | EP1928444A2 Use of ambroxol for the treatment of rhinovirus infections |
| 06/11/2008 | EP1928443A1 2-aminoalcohols for the treatment of neurodegenerative diseases |
| 06/11/2008 | EP1928442A2 Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof |
| 06/11/2008 | EP1928441A2 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation |
| 06/11/2008 | EP1928440A2 Treatment of eye disorders with sirtuin modulators |
| 06/11/2008 | EP1928439A2 Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear |
| 06/11/2008 | EP1928438A2 Use of ibudilast for treating drug and behavioral addictions |
| 06/11/2008 | EP1928437A2 Neurogenesis by muscarinic receptor modulation |
| 06/11/2008 | EP1928436A2 Application system for a plaster containing an active ingredient and a controlled-release agent for said active ingredient |
| 06/11/2008 | EP1928435A2 Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| 06/11/2008 | EP1928433A2 Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom |
| 06/11/2008 | EP1928431A2 Controlled release pharmaceutical composition containing carvedilol |
| 06/11/2008 | EP1928430A1 Pharmaceutical compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto |
| 06/11/2008 | EP1928428A2 A pharmaceutical formulation containing olanzapine |
| 06/11/2008 | EP1928427A1 Novel dosage formulation |